Actelion Ltd. CFO to Leave Company

Published: Aug 27, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actelion Ltd. (ATLN), the Swiss drugmaker that gets almost 90 percent of sales from a treatment for a rare lung disease, said Andre Muller will replace Chief Financial Officer Andrew Oakley, who is leaving the company. Muller, 49, will start the position on Sept. 1, the Allschwil-based company said in a statement today. Oakley, 51, is leaving to “focus on opportunities outside Actelion,” the drugmaker said.

Help employers find you! Check out all the jobs and post your resume.

Back to news